Medical treatment of gastroesophageal reflux disease - Beyond the proton pump inhibitors

Digestive Diseases

Volumn 18, Issue 1, 2000, Pages 7-13

  Holloway, Richard H ^a   Dent, John ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Acid suppression; Developments; Lower esophageal sphincter; Mucosal protection

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ATROPINE; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; EPIDERMAL GROWTH FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; MORPHINE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROTON PUMP INHIBITOR; SEROTONIN ANTAGONIST; SOMATOSTATIN; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; DRUG TARGETING; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER PRESSURE; PRIORITY JOURNAL; STOMACH PROTECTION;

EID: 0034046955     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016928     Document Type: Article

References (67)

1. Grove O, Bekker C. Jeppe-Hansen MG, Karstoft E, Sanchez G, Axelsson CK, Nielsen HO, Andersen B, Rask-Madsen J: Ranitidine and high-dose antacid in reflux oesophagitis. Scand J Gastroenterol 1985;20:457-461.
2. Goldin GF, Marcinkiewicz M, Zobroch T, Bityutskiy LP, McCallum RW, Sarosiek J: Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease. Dig Dis Sci 1997;42:1362-1369.
3. Holloway RH, Dent J: Pathophysiology of gastroesophageal reflux. Lower esophageal sphincter dysfunction in gastroesophageal reflux disease. Gastroenterol Clin North Am 1990;19: 517-535.
4. Penagini R, Schoeman MN, Dent J, Tippett MD, Holloway RH: Motor events underlying astro-oesophageal reflux in ambulant patients with reflux oesophagitis. Neurogastroenterol Motil 1996;8:131-141.
5. Dent J, Holloway RH, Toouli J, Doods WJ: Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastroesophageal reflux. Gut 1988;29:1020-1028.
6. Venables T, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML: Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-973.
7. Venables TL, Newland RD, Patel AC, Hole J, Copeman MB, Turbitt ML: Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol 1997;32:627-632.
8. Galmiche JP, Barthelemy P, Hamelin B: Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-773.
9. 1 agonist, on the frequency of transient lower oesophageal sphincter relaxations and gstro-ocsophageal reflux in healthy subjects. Am J Gastroenterol 1999;94:3158-3164.
10. Miltal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J: Transient lower esophageal sphincter relaxation. Gastroenterology 1995; 109:601-610.
11. Hornby P: How are transient LES relaxations triggered? In Guili R, Galmiche JP, Jamieson GG, Scarpignato C (eds): The Esophagogastric Junction. Paris, Libbey Eurotext, 1998, pp 62-72.
12. Mittal RK, Chiareli C, Liu J, Holloway RH, Dixon W Jr: Atropine inhibits gastric distension and pharyngeal receptor mediated lower oesophageal sphincter relaxation. Gut 1997;41 : 285-290.
13. Lidums I, Checklin H, Mittal RK, Holloway RH: Effect of atropine on gastro-oesophageal reflux and transient lower oesophageal sphincter relaxations in patients with gastro-oesophageal reflux disease. Gut 1998;43:12-16.
14. Koerselman J, Pursnani KG, Peghini P, Mohiuddin MA, Katzka D, Akkermans LM, Castell DO: Different effects of an oral anticholinergic drug on gastroesophageal reflux in upright and supine position in normal, ambulant subjects: A pilot study. Am J Gastroenterol 1999, 94:925-930.
15. Boulant J, Mathieu S, D'Amato M, Abergel A, Dapoigny M, Bommelaer G: Cholecystokinin in transient lower oesophageal sphincter relaxation due to gastric distension in humans. Gut 1997;40:575-581.
16. Clave P, Gonzalez A, Moreno A, Lopez R, Farre A, Cusso X, D'Mato M, Azpiroz F, Lluis F: Endogenous cholecyslokinin enhances post-prandial gastroesophageal reflux in humans through extrasphineteric receptors. Gastroenterology 1998;115:597-604.
17. Boeckxstaens GE, Hirsch DP, Fakhry N, Holloway RH, D'Amato M, Tytgat GN: Involvement of cholecystokinin-A receptors in transient lower esophageal sphincter relaxations triggered by gastric distension. Am J Gastroenterol 1998;93:1823-1828.
18. Malesci A, De Fazio C, Festorazzi S, Bonato C, Valentini A, Tacconi M, Rovati L, Setnikar I: Effect of loxiglumide on gallbladder contractile response to cerulein and food in humans. Gastroenterology 1990;98:1307-1310.
19. Calam J, Gibbons A: Letter to editor. Eur J Clin Invest 1995;25:214.
20. Hirsch DP, Holloway RH, Tytgat GNJ, Boeckxstaens GE: Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary persistalsis. Gastroenterology 1998;115:1374-1380.
21. Hirsch DP, Tiel-Van Buul MM, Tytgat GNJ, Boeckxstaens GEE: Effect of L-NMMA on post-prandial transient lower esophageal sphincter relaxations in healthy volunteers (abstract). Neurogastroenterol Motil 1999;11:264.
22. Penagini R, Bianchi PA: Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology 1997;113:409-414.
23. Allocca M, Mangano M, Colombo P, Bianchi PA, Penagini R: Does loperamide decrease gastroesophageal reflux in patients with reflux disease (abstract). Gastroenterology 1999;116: A111.
24. Rogers RC, McCann MJ, Stephens RL: Evidence for glutamate as a neurotransmitter in the gastric mechanoreceptor afferents projecting to the nucleus of the solitary tract (abstract). Soc Neurosci 1990;16:865.
25. Hshim MA, Bolger GT, Bieger D: Modulation of solitarial deglutitive N-methyl-D-aspartate receptors by dihydropyridines. Neuropharmacology 1989;28:923-929.
26. Lehmann A. Effects of an N-methyl-D-aspartate receptor antagonist on transient lower esophageal sphincter relaxations in the dog (abstract). Gastroenterology 1998;114:A787.
27. 3 receptors in the control by cholecystokinin of transient relaxations of the inferior esophageal sphincter in dogs (French). Gastroentérol Clin Biol 1996;20:575-580.
28. Blackshaw LA: Gastro-oesophageal afferent and serotonergic inputs to vagal efferent neurones. J Auton Nerv Syst 1994;49:93-103.
29. Cunningham ETJ, Sawchenko PE: A circumscribed projection from the nucleus of the solitary tract to the nucleus ambiguus in the rat: Anatomical evidence for somatostatin-28-immunoreactive interneurons subserving reflex control of esophageal motility. J Neurosci 1989;9:1668-1682.
30. Straathof JW, Tielman S, Lamers CBHW, Masclee AAM: Somatostatin prevents meal-induced alterations in lower esophageal sphincter function. Gut 1996;39(suppl 3):445.
31. Gunshefski LA, Rifley WJ, Slattery DW, Schifini JJ, Hartsuck M, Little AG: Somatostatin stimulation of the normal esophagus. Am J Surg 1992;163:59-62.
32. B receptor agonists. Am J Physiol 1999;277:G867-G874.
33. B receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999;117: 1147-1154.
34. B agonist baclofen in normal human subjects. Gastroenterology 2000;118:7-13.
35. Bowery NG, Pratt GD: GABA-B receptors as targets for drug action. Arzneimittelforschung 1992;42:215-223.
36. Brooks PA, Glaum SR, Miler RJ, Spyer KM: The actions of baclofen on neurones and synaptic transmission in the nucleus tractus solitarii of the rat in vitro. J Physiol (Lond) 1992;457: 115-129.
37. Bolser DC, DeGennaro FC, O'Reilly S, Chapman RW, Kreutner W, Egan RW, Hey JA: Peripheral and central sites of action of GABA-B agonists to inhibit the cough reflex in the cat and guinea pig. Br J Pharmacol 1994;113: 1344-1348.
38. Andrews PL, Bingham S, Wood KL: Modulation of the vagal drive to the intramural cholinergic and non-cholinergic neurones in the ferret stomach by baclofen. J Physiol 1987;388:25-39.
39. Kaupmann K, Huggel K, Heid J, Flor PJ, Bischoff S. Mickel SJ, McMaster G, Angst C, Bittiger H, Froestl W, Bettler B: Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature 1997;386:239-246.
40. Abrahams TP, Hornby PJ: Lower esophageal sphincter relaxation evoked by stimulation of the dorsal motor nucleus of the vagus in ferrets (abstract). Gastroenterology 1999;116:A589.
41. Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763-767.
42. Katz PO, Anderson C, Khoury R, Castell DO: Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998;12:1231-1234.
43. Howden CW, Forrest JAH, Reid JL: Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 1984;25:707-710.
44. Elm M, Hellke P, Andren K, Dahl G, Nyth AL: Time to relief of episodic symptoms of gastrooesophageal reflux disease. A crossover comparison of single doses of the effervescent and standard formulations of ranitidine. Scand J Gastroenterol 1998;33:900-904.
45. Johannessen T, Kristensen P: On-demand therapy in gastroesophageal reflux disease: A comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tablets. Clin Ther 1997;19:73-81.
46. Bate CM, Riley SA, Chapman RW, Durnin AT, Taylor MD: Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:59-66.
47. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HPM, Jansen EH, Tuynman HARE, Scrijver M, Dielman LA, Meuwissen SGM: Omeprazole as a diagnostic tool in gastro-esophageal reflux disease. Am J Gastroenterol 1997;92:1997-2000.
48. Wurst W, Hartmann M: Current status of acid pump antagonists (reversible PPIs). Yale J Biol Med 1996;69:233-243.
49. Martinek J, Blum AL, Stolte M, Hartmann M, Verdu EF, Luhmann R: Effects of pumaprazole (BY-841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:27-34.
50. Orlando RC: Esophageal epithelial defenses against acid injury. Am J Gastroenterol 1994; 89:1.
51. Tobey NA, Carson JL, Alkiek RA, Orlando RC: Dilated intercellular spaces: A morpholoigcal feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996; 111:1200-1205.
52. Zijstra FG, Hynna-Liepert TT, Dinda PK, Beck IT, Paterson WG: Microvascular permeability increases early in the course of acidinduced esophageal injury. Gastroenterology 1991;101:295-302.
53. Sarosiek J, Scheurich CJ, Marcinkiewicz M, McCallum RW: Enhancement of salivary esophagoprotection: Rationale for a physiological approach to gastroesophageal reflux disease. Gastroenterology 1996;110:675-681.
54. Sarosiek J, Feng T, McCallum RW: The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat. Am J Med Sci 1991;302:359-363.
55. Namiot Z, Rourk RM, Piascik R, Hetzel DP, Sarosiek J, McCallum RW: Interrelationship between esophageal challenge with mechanical and chemical stimuli and salivary protective mechanisms. Am J Gastroenterol 1994;89: 581-587.
56. 2 in humans. Am J Med Sci 1997;313:90-98.
57. Marcinkiewicz M, Namiot Z, Edmunds MC, McCallum RW, Sarosiek J: Detrimental impact of acid and pepsin on the rate of luminal release of transforming growth factor alpha. Its potential pathogenetic role in the development of reflux esophagitis. J Clin Gastroenterol 1996;23:261-268.
58. Namiot Z, Sarosiek J, Rourk RM, Hetzel DP, McCallum RW: Human esophageal secretion: Mucosal response to luminal acid and pepsin. Gastroenterology 1994;106:973-981.
59. Sarosiek J, Yu Z, Namiot Z, Rourk RM, Hetzel DP, McCallum RW: Impact of acid and pepsin on human esophageal prostaglandins. Am J Gastroenterol 1994;89:588-594.
60. 2 in patients with reflux esophagitis under the impact of acid and acid/pepsin solutions. Its potential pathogenetic significance. J Clin Gastroenterol 1995;21:268-274.
61. Rourk RM, Namiot Z, Edmunds MC, Sarosiek J, Yu Z, McCallum RW: Diminished luminal release of esophageal epidermal growth factor in patients with reflux esophagitis. Am J Gastroenterol 1994;89:1177-1184.
62. Sonnenberg A, Steinkamp U, Weise A, Berges W, Wienbeck M, Rohner HG, Peter P: Salivary secretion in reflux esophagilis. Gastroenterology 1982;83:889-895.
63. Gangarosa LM, Dempsey PJ, Damstrup L, Barnad JA, Coffey RJ: Transforming growth factor-α. Baillières Clin Gastroenterol 1996;10: 49-63.
64. Goodland RA, Wright NA: Epidermal growth factor. Baillières Clin Gastroenterol 1996;10: 33-47.
65. Katz PO, Geisinger KR, Hassan M, Wu WC, Huang D, Castell DO: Acid-induced esophagitis in cats is prevented by sucralfate but not synthetic prostaglandin E. Dig Dis Sci 1988;33: 217-224.
66. Smart HL, James PD, Atkinson M, Hawkey CJ: Treatment of reflux oesophagitis with trimoprostil. Digestion 1989;44:52-56.
67. Purushotham AD, Gray GR, Hansell DT: Prostaglandins in the treatment of reflux oesophagitis: Double-blind placebo-controlled clinical trial. J R Coll Surg Edin 1991;36:216-218.